Geert Mayer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Dirk M. Hermann

    Department of Neurology and Center for Translational Neuro-and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany

    2 shared publications
  • Janine Gronewold

    Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS) University Hospital Essen, University Duisburg-Essen, Essen, Germany

    2 shared publications
  • Anne-Françoise Schlit

    UCB Pharma, Braine-l'Alleud, Belgium

    1 shared publication
  • Carla Stenmanns

    Department of Orthopedics and Trauma Surgery, Age trauma center, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University, Düsseldorf, Germany

    1 shared publication
  • Carla Stenmanns

    Klinik für Orthopädie und Unfallchirurgie/Altersmedizin, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland

    1 shared publication
  • Didier Wuiame

    UCB Pharma, Brussels, Belgium

    1 shared publication

Latest Publications

  • Open Access

    A step further towards scientific arguments for expert witnesses in the defense of patients accused of forensic parasomnias

    by Geert Mayer

    Whoever sat in court to defend a patient accused for sexual assault or violence during sleep knows about the paucity of objective and scientific arguments for a sleep expert witness that often stands against the conviction of legal and public morals. The article by Peretti et al. [ 1] provides new important arguments that help the expert witness to clarify if the assaults under accusation are caused by a disorder of arousal (DOA) with or without sexsomnia or if the latter is pretended. Apart from these arguments, public opinion needs to get a different view on this deviant behavior, which is not intentional, but occurs in a state of blurred/lack of awareness/consciousness due to a dissociated state between wake and sleep. The judges and the jury must understand and be convinced that an underlying sleep disorder may be the cause. The task of sleep experts is to prove the sleep disorder with strong scientific arguments.


  • Open Access

    Associations of sleep disorders with all-cause MCI/dementia and different types of dementia – clinical evidence, potential pathomechanisms and treatment options: A narrative review

    by Geert Mayer, Helmut Frohnhofen, Martha Jokisch, Dirk M. Hermann, Janine Gronewold

    Due to worldwide demographic change, the number of older persons in the population is increasing. Aging is accompanied by changes of sleep structure, deposition of beta-amyloid (Aß) and tau proteins and vascular changes and can turn into mild cognitive impairment (MCI) as well as dementia. Sleep disorders are discussed both as a risk factor for and as a consequence of MCI/dementia. Cross-sectional and longitudinal population-based as well as case–control studies revealed sleep disorders, especially sleep-disorderded breathing (SDB) and excessive or insufficient sleep durations, as risk factors for all-cause MCI/dementia. Regarding different dementia types, SDB was especially associated with vascular dementia while insomnia/insufficient sleep was related to an increased risk of Alzheimer’s disease (AD). Scarce and still inconsistent evidence suggests that therapy of sleep disorders, especially continuous positive airway pressure (CPAP) in SDB, can improve cognition in patients with sleep disorders with and without comorbid dementia and delay onset of MCI/dementia in patients with sleep disorders without previous cognitive impairment. Regarding potential pathomechanisms via which sleep disorders lead to MCI/dementia, disturbed sleep, chronic sleep deficit and SDB can impair glymphatic clearance of beta-amyloid (Aß) and tau which lead to amyloid deposition and tau aggregation resulting in changes of brain structures responsible for cognition. Orexins are discussed to modulate sleep and Aß pathology. Their diurnal fluctuation is suppressed by sleep fragmentation and the expression suppressed at the point of hippocampal atrophy, contributing to the progression of dementia. Additionally, sleep disorders can lead to an increased vascular risk profile and vascular changes such as inflammation, endothelial dysfunction and atherosclerosis which can foster neurodegenerative pathology. There is ample evidence indicating that changes of sleep structure in aging persons can lead to dementia and also evidence that therapy of sleep disorder can improve cognition. Therefore, sleep disorders should be identified and treated early.


  • Schlaf und Demenz

    by Geert Mayer, Carla Stenmanns, Thorsten R. Doeppner, Dirk M. Hermann, Janine Gronewold

    Zusammenfassung Altern geht mit Änderungen der Schlafstruktur sowie zerebraler Ablagerung von Amyloid‑β und Tau-Proteinen einher. Schlafstörungen gehen dem Beginn einer Demenz um Jahre voraus. Komorbide Schlafstörungen wie Insomnien und schlafbezogene Atmungsstörungen, familiäre Demenzbelastung und epigenetische Faktoren können zur Demenzentwicklung beitragen. Dieser Beitrag geht der Frage nach der Interaktion zwischen Schlaf und Demenz anhand von bisher existierender Literatur nach. Veränderungen von „slow wave sleep“ führen zu Änderungen der glymphatischen Clearance von Amyloid‑β, Tau- und anderen Proteinen. Transiente und chronifizierte Schlafstörungen verursachen Veränderungen in Gehirnarealen, die für Kognition und Verhalten verantwortlich sind. Schlafregulierende Hirnareale sind als erste im neurodegenerativen Prozess betroffen und beschleunigen das Demenzrisiko. Zirkadiane altersbedingte Änderungen von Amyloid‑β und Tau-Protein beeinflussen die Schlafmenge bzw. -tiefe und umgekehrt. Die Liquor-Aβ-Konzentration weist eine inverse Korrelation mit dem Schlaf auf. Orexine modulieren Amyloid‑β und Schlaf.


  • Frailty phenotype and risk factor for disturbed sleep

    by Helmut Frohnhofen, Carla Stenmanns, Janine Gronewold, Geert Mayer

    Zusammenfassung Frailty hat – unabhängig von der Art ihrer Operationalisierung – erhebliche negative Folgen für den Betroffenen und die Solidargemeinschaft. Auch wenn eine allgemein akzeptierte Definition von Frailty noch fehlt, besteht an der Existenz dieses Phänomens kein Zweifel. Pathophysiologisch wird ein dysfunktionales Zusammenspiel komplexer Systeme diskutiert. Therapeutische Konzepte zeigen, dass Frailty ein dynamischer Zustand ist, der verbessert werden kann. Die pathophysiologischen Charakteristika von Frailty und gestörtem Schlaf weisen zahlreiche Gemeinsamkeiten auf. Zudem findet sich das Frailty häufiger bei Schlafgestörten. Da die Mehrzahl der Schlafstörungen gut behandelbar ist, sollte ein Screening auf Schlafstörungen in ein umfassendes Konzept zum Management von Frailty integriert werden.

  • The need for new instruments to measure the manyfold aspects of excessive daytime sleepiness

    by Geert Mayer

    Geert Mayer; The need for new instruments to measure the manyfold aspects of excessive daytime sleepiness, Sleep, , zsac144, https://doi.org/10.1093/sleep/zsac1


  • Open Access

    Insomnia in neurological diseases

    by Geert Mayer, Svenja Happe, Stefan Evers, Wiebke Hermann, Sabine Jansen, Ulf Kallweit, Maria-Lucia Muntean, Dieter Pöhlau, Dieter Riemann, Michael Saletu, et al.

    Insomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime performance. These components of insomnia – namely persistent sleep difficulties despite of adequate sleep opportunity resulting in daytime dysfunction - appear secondary or co-morbid to neurological diseases. Comorbid insomnia originates from neurodegenerative, inflammatory, traumatic or ischemic changes in sleep regulating brainstem and hypothalamic nuclei with consecutive changes of neurotransmitters. Symptoms of neurological disorders (i.e motor deficits), co-morbidities (i.e. pain, depression, anxiety) and some disease-specific pharmaceuticals may cause insomnia and/or other sleep problems.This guideline focuses on insomnias in headaches, neurodegenerative movement disorders, multiple sclerosis, traumatic brain injury, epilepsies, stroke, neuromuscular disease and dementia.The most important new recommendations are: Cognitive behavioral therapy (CBTi) is recommended to treat acute and chronic insomnia in headache patients. Insomnia is one of the most frequent sleep complaints in neurodegenerative movement disorders. Patients may benefit from CBTi, antidepressants (trazodone, doxepin), melatonin and gaba-agonists. Insomnia is a frequent precursor of MS symptoms by up to 10 years. CBTi is recommended in patients with MS, traumatic brain injury and. Melatonin may improve insomnia symptoms in children with epilepsies. Patients with insomnia after stroke can be treated with benzodiazepine receptor agonists and sedating antidepressants. For patients with dementia suffering from insomnia trazodone, light therapy and physical exercise are recommended.


  • Open Access

    Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy

    by Steven T. Szabo, Michael J. Thorpy, Geert Mayer, John H. Peever, Thomas S. Kilduff